June 11, 2019 7:54am

News: Mesoblast Limited (MESO) expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan to the use of mesenchymal stem cells (MSCs) for the treatment of newborns that lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy (HIE). Intrexon Corp (XON) CEO Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share

Pre-open indications: 5 BUYs, 0 SELLs and 3 TRADES

We crave explanations because they give us an illusion of control...

 

The philosopher Friedrich Nietzsche once observed that "any explanation is better than none." I disagree. Sometimes, in the investment world, no explanation is really necessary — or relevant.

 

Dow futures are UP +0.45% (+118 points), S&P futures are UP +0.46% (+14 points) and NASDAQ futures are also UP +0.66% (+50 points)

 

U.S. stock index futures rallied again despite comments from President Trump on trade war with China.

European stocks traded higher after U.S. President Donald Trump told CNBC that immediate tariffs would be imposed on a further $300 billion of Chinese goods if President Xi does not attend this month’s G-20 meeting while the pan-European Stoxx 600 rose 0.9% during the morning session,

Asian Pacific shares especially in mainland China surged on a signal of an infrastructure boost from Beijing outweighed comments from U.S. President Trump on the ongoing trade war; Australia shares traded higher after returning from a holiday

 

Data docket: the National Federation of Independent Business survey at 6 a.m. ET as well as of the latest producer price index numbers at 8:30 a.m.

 

Henry’omics:  

We are set for a positive open with the NASDAQ seen higher.

Although after two (2) positive closes to end last week, Monday “rang” a neutral tone; so be prepared for some “skinny” movement!

The question of the day or this week – WHAT are we pinning our share pricing hopes on news (?) , milestones or catalysts (?) or the fact that the … MAHINES (computer driven trading) are “RULING”?

 

From Monday night’s post, “take a pew for news of share pricing exhibiting a risk on/off status.”

  • The close was neutral with an A/DL of 21/21 and 1 flat and 2 acquired;
  • The range of the 21 upside was +0.35% (IONS) to +25.06% (ONVO +$0.11) while the 21 downside ranged from -0.63% (VYGR) to -9.80% (RENE.L);
  • 9 out of the 21 downside had higher than the 3 month average volume;
  • 6 out of the 21 upside had higher than the 3 month average volume;
  • The iShares NASDAQ Biotechnology (IBB) indicator:  closed down -0.17% after Friday’s +1.62%;

Q2/19 so far:

  • In June, there were 3 positive, 1 neutral and 2 negative close, so far;
  • In May, there were 14 negative, 1 holiday and 8 positive closes;
  • In April, there has been 10 positive and 11 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context: post earnings release:

AxoGen (AXGN) closed down -$1.28 to $19.32 after Friday’s $20.60, Thursday’s $21.10, Wednesday’s $22.24 and last Tuesday’s $22.16 – Oversold, BUY;

bluebird bio (BLUE) closed down again -$8.12 to $118.31 after Friday’s -$2.76 to $122.01, Wednesday’s -$4.67 to $124.77 and last Tuesday’s +$7.02 to $129.44 following the previous Monday’s $122.42 and Friday’s $119.92 - Maintaining BUY;

CRISPR Therapeutics (CRSP) closed up +$1.50 to $44.38 after Friday’s +$5.63 to $42.88, Thursday’s -$0.28 to $37.25, Wednesday’s +$0.27 to $37.53, Tuesday’s +$1.27 to $37.26 and last Monday’s +$0.42 to $35.99 as May 1st opened at $38.82, Still believe it’s overbought, – TRADE;

Editas Medicine (EDIT) closed down -$0.36 to $22.05 after Friday’s +$1.83 to $22.41, Thursday’s +$0.10 to $20.58, Wednesday’s -$0.35 to $20.48 and last Tuesday’s +$0.07 to $20.83 following the previous Monday’s +$0.21 to $20.76 and Friday’s -$0.68 to $20.55 – TRADE;

Intellia Therapeutics (NTLA) closed down -$0.70 to $14.36 after Friday’s +$0.80 to $15.06, Thursday’s -$0.40 to $14.25, Wednesday’s-$0.03 to $14.66 and last Tuesday’s +$0.44 to $14.69 following the previous Monday’s +$0.37 to $14.25 and Friday’s -$0.62 to $13.88 – TRADE;

Mesoblast (MESO) closed up +$0.06 to $5.10 with aftermarket news (above) after Friday’s $5.03, Thursday’s $5.12, Wednesday’s $5.04 and last Tuesday’s $4.89. There is a market time differential with a positive and upside of +$0.03 ($5.13) – BUY;

ReNeuron (RENE.L) closed down another -$25.00 to $230.00 after Friday’s -$10.50 and Thursday -$10.50, Wednesday’s -$22.00 and last Tuesday’s -$5.00 to $295.00 following the previous Monday’s -$5.00 to $300.00 and Friday’s at $305.00. RENE.L has a time differential trading with a market upside of $19.50 – SELL to BUY;

Intrexon Corp (XON) closed up +$0.15 to $5.55 after Friday’s $5.40, Thursday’s $5.34, Wednesday’s $5.57 and last Tuesday’s $5.24 - CEO Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share – a stimulus from a stock that got hammered after quarterly earnings – BUY;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.